Home » Vertex Receives Australian Approval for Kalydeco
Vertex Receives Australian Approval for Kalydeco
Australia’s Therapeutic Goods Administration has approved Vertex’s Kalydeco, a drug that treats the underlying cause of cystic fibrosis in patients with the G551D mutation.
Businesswire
Businesswire
Upcoming Events
-
07May
-
14May
-
30May